immunitybio.com (IBRX) - Company Cash Volume

Official company branding of ImmunityBio, Inc. (IBRX)

ImmunityBio, Inc. (IBRX) is facing a liquidity shortage due to the costs associated with bringing new drugs to market. Strategic partnerships with clinics are accelerating vaccine trials, which is reflected in the cash position. The value of 0.33 reflects the baseline level of the metric. Meanwhile, IBRX quotes depend on medical breakthroughs rather than market cycles, which only affect the cost of borrowing.

IBRX - ImmunityBio Corp Company Cash Reserve over the range 07/04/2022 - 11/21/2026

Analytical breakdowns for ImmunityBio, Inc.

- current price and projected stock value:
Fundamental company valuation:ImmunityBio Inc IBRX
Brand item of ImmunityBio

This indicator measures the volume of liquid funds and equivalents available for operational liability coverage, excluding unrealized gains. By analyzing the current cash position, an investor sees the aggregated cash balances, which is critically important for ImmunityBio, Inc. (IBRX), as its ambitious oncology developments require colossal expenditures amid polarized market sentiment regarding the volatility of its clinical data.